Clinical trials: Dermatitis Eczema
Atopic Dermatitis
Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects
The goal of this two-sequence, two-cycle, single and multiple-dose Phase I clinical trial is To evaluate the human bioequivalence of the test preparation and the reference preparation in 28 healthy chinese subjects at a single…
- Trial name
- NCT05945810
- Testing
- TLL-018 extended-release tablet, TLL-018 immediate-release tablet
- Where
- China
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Atopic Dermatitis
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for…
- Trial name
- Rising Up (NCT03661138)
- Testing
- Upadacitinib, Topical Corticosteroids (TCS)
- Where
- 43 sites in Japan
- Volunteers
- 272 people
- Sponsor
- AbbVie
Atopic Dermatitis
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002), given every 2 weeks for 7 doses, in adult subjects with…
- Trial name
- ATLAS (NCT05155085)
- Testing
- AK002
- Where
- 55 sites in United States, Germany
- Volunteers
- 131 people
- Sponsor
- Allakos Inc.
Atopic Dermatitis
A Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of SUN13834 in Adult Subjects With Atopic Dermatitis
The purpose of the study is to explore the efficacy and safety of SUN13834 vs placebo in adult participants with atopic dermatitis.
- Trial name
- NCT00717769
- Testing
- SUN13834
- Where
- 28 sites in United States
- Volunteers
- 270 people
- Sponsor
- Daiichi Sankyo
Atopic Dermatitis
A Study of CM310 in Children Patients With Moderate-to-severe Atopic Dermatis
This is a multi-center, single arm, open-label study to evaluate safety and primary efficacy in children patients with moderate-to severe atopic dermatis.
- Trial name
- NCT05579925
- Testing
- CM310
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Keymed Biosciences Co.Ltd
Atopic Dermatitis (AD)
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
This is a double-blind, placebo-controlled study where subjects are participating for approximately 36 to 40 weeks. The study compares how well BFB759 works and how safe it is compared with a placebo.
- Trial name
- COMPASS 2-AD (NCT07105488)
- Testing
- BFB759
- Where
- 88 sites in United States, Bulgaria and 5 more
- Volunteers
- 225 people
- Sponsor
- Bluefin Biomedicine, Inc.
Atopic Dermatitis Eczema
Study in Subjects With Moderate Atopic Dermatitis
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in…
- Trial name
- NCT03859986
- Testing
- ALX-101 Gel Vehicle, ALX-101 Gel 5%
- Where
- 22 sites in United States, Canada
- Volunteers
- 124 people
- Sponsor
- Ralexar Therapeutics, Inc.
Atopic Dermatitis
Study of MG-K10 Humanized Monoclonal Antibody Injection in Patients With Atopic Dermatitis
The study is to reflect the effectiveness and safety of MG-K10 humanized monoclonal antibody injection in patients with moderate to severe atopic dermatitis.administered every 4 weeks for 52 week
- Trial name
- NCT06026891
- Where
- China
- Volunteers
- 498 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial, aiming to evaluate the efficacy, safety, and tolerability of CMS-D001 in participants with moderate to severe atopic dermatitis…
- Trial name
- NCT07465120
- Testing
- CMS-D001 50mg, CMS-D001 100mg, CMS-D001 200mg
- Where
- 28 sites in China
- Volunteers
- 160 people
- Sponsor
- Dermavon Holdings Limited
Atopic Dermatitis
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
- Trial name
- NCT06055361
- Testing
- BxC-I17e (primed iMSC derived Extracellular vesicles(EV))
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Brexogen Inc.
Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).
- Conditions
- Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD)
- Trial name
- CLEAR-AD1 (NCT06855745)
- Testing
- zabalafin
- Where
- 12 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Alphyn Biologics
Eczema, Atopic Dermatitis
A Clinical Trial to Evaluate the Effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in Adults With Eczema-Prone Skin
This is a single-arm, open-label, decentralized (fully remote) clinical trial evaluating the tolerability and self-perceived skin effects of Rejuvaskin Eczema Body Wash and Skin Recovery Cream in 35 adults aged 18-65 with…
- Conditions
- Eczema, Atopic Dermatitis, Eczema-Prone Skin
- Trial name
- NCT07700745
- Testing
- Rejuvaskin Eczema Body Wash
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Rejuvaskin
Atopic Dermatitis
Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderate to Severe Chronic Atopic Dermatitis(AD)
This is multi-center, randomized, double-blind, parallel, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of FURESTEM-AD Inj. for moderate to severe chronic atopic dermatitis
- Trial name
- NCT03269773
- Testing
- FURESTEM-AD Inj.
- Where
- 11 sites in South Korea
- Volunteers
- 197 people
- Sponsor
- Kang Stem Biotech Co., Ltd.
Healthy, Atopic Dermatitis
A Study of LY3872386 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to evaluate the safety and tolerability of LY3872386 in healthy participants and participants with atopic dermatitis. The safety of prednisone is also evaluated in healthy participants.
- Trial name
- NCT06119529
- Testing
- LY3872386, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
A Phase Ⅱ Study of Hemay808 for Atopic Dermatitis Patients
Assess Hemay808 concentration of 1%/3%/7% for treatment of mild and moderate adult atopic dermatitis patients.
- Trial name
- NCT04352595
- Testing
- Hemay808
- Where
- 2 sites in China
- Volunteers
- 148 people
- Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
Atopic Dermatitis
A First-In-Human Study to Evaluate the Safety, Tolerability, and Efficacy of Si-544 in Adults With Atopic Dermatitis
This is a multi-center, Phase 1b, double-blind, placebo-controlled, SAD and MAD, first-in-human study in subjects with mild to severe AD receiving si-544. The study consists of 2 parts, an SAD and an MAD part.
- Trial name
- NCT05383378
- Testing
- si-544
- Where
- 5 sites in Germany
- Volunteers
- 36 people
- Sponsor
- selectION Therapeutics GmbH
Dermatitis, Atopic
An Observational Study Investigating the Treatment Satisfaction of Atopic Dermatitis Patients Who Have Switched to Ointment (W/O Emulsion) Formulation of Very Strong Class Topical Corticosteroids
This study intends to investigate patient satisfaction of treatment with Ointment (W/O emulsion) formulations of Potency Class II topical corticosteroids (TCs) for atopic dermatitis (AD) patients in Japan.
- Trial name
- Ointment TS-AD (NCT02627989)
- Testing
- Diflucortolone valerate (Nerisona), Diflucortolone valerate (Texmeten)
- Where
- Japan
- Volunteers
- 55 people
- Sponsor
- LEO Pharma
Dermatitis, Atopic
A Study of LY3454738 in Healthy Participants and Participants With Atopic Dermatitis
The main purpose of this study is to investigate the safety, tolerability, and efficacy of the study drug known as LY3454738 in healthy participants and participants with atopic dermatitis. The study has three parts.
- Trial name
- NCT03750643
- Testing
- LY3454738
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Atopic Dermatitis
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Atopic Dermatitis
This is an open-label, safety study designed to assess the multiple-dose pharmacokinetics and potential for adrenal suppression following topical treatment with halobetasol propionate 0.05% spray applied twice-daily in adult…
- Trial name
- NCT03245385
- Testing
- Treatment with Halobetasol propionate 0.05% topical spray
- Where
- 13 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sun Pharmaceutical Industries Limited
Atopic Dermatitis
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
The purpose of this study is to evaluate the long-term safety and efficacy of baricitinib in participants with atopic dermatitis.
- Trial name
- BREEZE-AD3 (NCT03334435)
- Testing
- Baricitinib
- Where
- 185 sites in Argentina, Australia and 17 more
- Volunteers
- 1,645 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.